US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
KR100458403B1
(ko)
*
|
1997-09-29 |
2004-11-26 |
포인트 써러퓨틱스, 인크. |
생체외 조혈세포의 자극방법
|
DE19823831A1
(de)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
DE19834591A1
(de)
*
|
1998-07-31 |
2000-02-03 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Steigerung des Blutglukosespiegels in Säugern
|
US6979697B1
(en)
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
WO2000053171A1
(fr)
*
|
1999-03-05 |
2000-09-14 |
Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. |
Utilisation de metformine dans la preparation de compositions pharmaceutiques pouvant inhiber l'enzyme dipeptidyl peptidase iv
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
CA2393825A1
(fr)
*
|
1999-12-17 |
2001-06-21 |
Versicor, Inc. |
Nouveaux composes a base de succinate, compositions les contenant, et procedes d'utilisation et de preparation de ceux-ci
|
JP2003520226A
(ja)
*
|
2000-01-21 |
2003-07-02 |
ノバルティス アクチエンゲゼルシャフト |
ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
JP2003523396A
(ja)
*
|
2000-02-25 |
2003-08-05 |
ノボ ノルディスク アクティーゼルスカブ |
ベータ細胞変性の抑制
|
DK1283735T4
(da)
*
|
2000-03-31 |
2013-02-04 |
Royalty Pharma Collection Trust |
Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
|
GB0010183D0
(en)
*
|
2000-04-26 |
2000-06-14 |
Ferring Bv |
Inhibitors of dipeptidyl peptidase IV
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
ATE556048T1
(de)
|
2000-08-10 |
2012-05-15 |
Mitsubishi Tanabe Pharma Corp |
Prolinderivate und ihre verwendung als heilmittel
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
EP1891948A1
(fr)
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Traitment de troubles neurologiques et neuropsychologiques
|
ZA200302394B
(en)
*
|
2000-10-27 |
2004-03-29 |
Probiodrug Ag |
Method for the treatment of neurological and neuropsychological disorders.
|
CA2433090A1
(fr)
*
|
2000-12-27 |
2002-07-04 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de dipeptidyl peptidase iv
|
PT1757606E
(pt)
*
|
2001-02-24 |
2009-05-26 |
Boehringer Ingelheim Pharma |
Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
US20070293426A1
(en)
*
|
2001-04-02 |
2007-12-20 |
Hans-Ulrich Demuth |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
ES2258141T3
(es)
|
2001-04-11 |
2006-08-16 |
Bristol-Myers Squibb Company |
Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US6944925B2
(en)
*
|
2001-06-13 |
2005-09-20 |
Ttx Company |
Articulated connector reconditioning process and apparatuses
|
HUP0400321A2
(hu)
|
2001-06-27 |
2004-08-30 |
Smithkline Beecham Corp. |
Fluorpirrolidin-származékok mint dipeptidil-dipeptidáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
|
DE10150203A1
(de)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Peptidylketone als Inhibitoren der DPIV
|
CN1321682C
(zh)
*
|
2001-06-27 |
2007-06-20 |
前体生物药物股份有限公司 |
新的二肽基肽酶iv抑制剂和它们作为抗癌药的用途
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
DE60223920T2
(de)
|
2001-06-27 |
2008-11-13 |
Smithkline Beecham Corp. |
Pyrrolidine als dipeptidyl-peptidase-inhibitoren
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
US7183290B2
(en)
|
2001-06-27 |
2007-02-27 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
JP2005504766A
(ja)
*
|
2001-08-16 |
2005-02-17 |
プロバイオドラッグ アーゲー |
プロリンエンドペプチダーゼ阻害剤の、細胞内シグナルカスケード依存性イノシトール(1,4,5)トリホスフェート濃度調節への使用。
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
KR20040033048A
(ko)
|
2001-09-14 |
2004-04-17 |
미츠비시 웰파마 가부시키가이샤 |
티아졸리딘 유도체 및 이의 약학적 용도
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
YU31004A
(sh)
|
2001-10-18 |
2006-08-17 |
Bristol-Myers Squibb Company |
Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
|
GB0125446D0
(en)
*
|
2001-10-23 |
2001-12-12 |
Ferring Bv |
Novel anti-diabetic agents
|
EP1338595B1
(fr)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Dérivés de Xanthines servant d'inhibiteurs de DPP-IV
|
EP1695970A1
(fr)
*
|
2002-02-28 |
2006-08-30 |
Prosidion Limited |
Peptides utilisés pour la modulation competitive de la catalyse de peptidase dipeptidyle IV
|
SI1480961T1
(sl)
*
|
2002-02-28 |
2007-06-30 |
Prosidion Ltd |
Inhibitorji dpiv na osnovi glutaminila
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
ES2306781T3
(es)
*
|
2002-08-09 |
2008-11-16 |
Prosidion Ltd. |
Inhibidores de la dipeptidil-peptidasa iv para disminucion de la tasa de aumento cronico de peso.
|
TW200404796A
(en)
*
|
2002-08-19 |
2004-04-01 |
Ono Pharmaceutical Co |
Nitrogen-containing compound
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
*
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
US20050176622A1
(en)
*
|
2002-09-18 |
2005-08-11 |
Kerstin Kuhn-Wache |
Secondary binding site of dipeptidyl peptidase IV (DPIV)
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
US6995180B2
(en)
|
2002-10-23 |
2006-02-07 |
Bristol Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
|
US7482337B2
(en)
*
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
DE10254304A1
(de)
*
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
EP1608317B1
(fr)
|
2003-03-25 |
2012-09-26 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
US20040229848A1
(en)
*
|
2003-05-05 |
2004-11-18 |
Hans-Ulrich Demuth |
Glutaminyl based DP IV-inhibitors
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
CN101837127A
(zh)
|
2003-05-05 |
2010-09-22 |
前体生物药物股份公司 |
谷氨酰胺酰基和谷氨酸环化酶效应物的应用
|
PL1620082T3
(pl)
|
2003-05-05 |
2010-10-29 |
Probiodrug Ag |
Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
|
US7638638B2
(en)
|
2003-05-14 |
2009-12-29 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7566707B2
(en)
*
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7470700B2
(en)
|
2003-08-13 |
2008-12-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CA2535971C
(fr)
|
2003-08-20 |
2018-04-10 |
Biosite, Inc. |
Methodes et compositions permettant de mesurer les peptides natriuretiques et d'ameliorer leur potentiel therapeutique
|
WO2005020983A2
(fr)
*
|
2003-09-02 |
2005-03-10 |
Prosidion Ltd. |
Therapie combinee de regulation glycemique
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
CN102302781A
(zh)
|
2003-10-15 |
2012-01-04 |
前体生物药物股份公司 |
谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
|
DE10348023A1
(de)
*
|
2003-10-15 |
2005-05-19 |
Imtm Gmbh |
Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
|
CA2544573A1
(fr)
|
2003-11-03 |
2005-06-02 |
Probiodrug Ag |
Combinaisons utiles au traitement de troubles neuronaux
|
CN1905876B
(zh)
|
2003-11-17 |
2010-06-09 |
诺瓦提斯公司 |
二肽基肽酶iv抑制剂的用途
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
DE10355304A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7504423B2
(en)
|
2003-12-11 |
2009-03-17 |
Mitsubishi Tanabe Pharma Corporation |
α-amino acid derivatives and use thereof as medicines
|
WO2005058894A1
(fr)
*
|
2003-12-19 |
2005-06-30 |
Altana Pharma Ag |
Intermediaires pour la preparation de derives de dihydropyrano-imidazopyridines tricycliques
|
CN101262851A
(zh)
*
|
2004-01-20 |
2008-09-10 |
诺瓦提斯公司 |
直接压片配方和方法
|
EP1715893B8
(fr)
|
2004-01-20 |
2009-12-16 |
Novartis Ag |
Formulation a compression directe et procede correspondant
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
CA2554809C
(fr)
|
2004-02-05 |
2014-04-29 |
Probiodrug Ag |
Nouveaux inhibiteurs de la glutaminyl-cyclase comportant de la n thiouree alkyle et de l'imidazolyl substitue par thioamide
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004009039A1
(de)
*
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
AU2004318013B8
(en)
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1586573B1
(fr)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
US7439370B2
(en)
*
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
JP2008501714A
(ja)
*
|
2004-06-04 |
2008-01-24 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼインヒビター
|
DE102004030502A1
(de)
*
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
WO2006019965A2
(fr)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Inhibiteurs de la dipeptidyl peptidase
|
AU2005267093B2
(en)
*
|
2004-07-23 |
2009-10-01 |
Nuada Llc |
Peptidase inhibitors
|
JP4854511B2
(ja)
*
|
2004-08-26 |
2012-01-18 |
武田薬品工業株式会社 |
糖尿病治療剤
|
PE20060652A1
(es)
|
2004-08-27 |
2006-08-11 |
Novartis Ag |
Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
|
DE102004043944A1
(de)
*
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
*
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP2008524331A
(ja)
*
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
CN102372704B
(zh)
|
2005-02-18 |
2014-10-08 |
田边三菱制药株式会社 |
脯氨酸衍生物的盐,其溶剂合物,及其生产方法
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
AU2006255097B2
(en)
|
2005-06-06 |
2012-02-09 |
Georgetown University |
Compositions and methods for lipo modeling
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
EP1910317B1
(fr)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
Composés joints en position 1-amino
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CN101232873A
(zh)
*
|
2005-08-11 |
2008-07-30 |
霍夫曼-拉罗奇有限公司 |
含有dpp-iv抑制剂的药物组合物
|
CA2622472C
(fr)
*
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
|
CN101360723A
(zh)
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
制备嘧啶二酮衍生物的方法
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JOP20180109A1
(ar)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
EP1971614A1
(fr)
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Derives de pyrrolidine a fusion de cyclopropyle, en tant qu'inhibiteurs de dipeptidyle peptidase iv (dp iv)
|
US8414921B2
(en)
|
2005-12-16 |
2013-04-09 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
WO2007112347A1
(fr)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
DK1971862T3
(da)
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EA200802054A1
(ru)
|
2006-04-12 |
2009-04-28 |
Пробиодруг Аг |
Ингибиторы фермента
|
JP5645360B2
(ja)
*
|
2006-04-21 |
2014-12-24 |
株式会社明治 |
ジペプチドを有効成分として含有する組成物
|
EP1852108A1
(fr)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20110235A1
(es)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2873524C
(fr)
|
2006-05-04 |
2018-02-20 |
Boehringer Ingelheim International Gmbh |
Une forme polymerique de 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
WO2007139589A1
(fr)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Modulateurs des récepteurs de glp-1 à libération prolongée
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
CA2660197A1
(fr)
*
|
2006-08-08 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Pyrrolo[3,2-d]pyrimidines utilisees en tant qu'inhibiteurs de dpp-iv pour le traitement du diabete sucre
|
WO2008028914A1
(fr)
|
2006-09-07 |
2008-03-13 |
Nycomed Gmbh |
Polythérapie contre le diabète sucré
|
AU2007296556B2
(en)
*
|
2006-09-13 |
2013-09-19 |
Takeda Pharmaceutical Company Limited |
Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
JP2010508358A
(ja)
|
2006-11-01 |
2010-03-18 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用
|
WO2008057862A2
(fr)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation
|
WO2008055945A1
(fr)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
SI2091948T1
(sl)
|
2006-11-30 |
2012-07-31 |
Probiodrug Ag |
Novi inhibitorji glutaminil ciklaze
|
AU2007340129B2
(en)
|
2006-12-26 |
2012-02-02 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
ES2529149T3
(es)
|
2007-04-03 |
2015-02-17 |
Mitsubishi Tanabe Pharma Corporation |
Una combinación de inhibidor de dipeptidil peptidasa IV y edulcorante para uso en el tratamiento de la obesidad
|
EP2142514B1
(fr)
|
2007-04-18 |
2014-12-24 |
Probiodrug AG |
Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2152663B1
(fr)
|
2007-06-04 |
2014-03-19 |
Ben Gurion University of the Negev Research and Development Authority |
Composés triarylés et compositions les comprenant
|
DK2170930T3
(da)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
|
EP2173717B9
(fr)
*
|
2007-07-27 |
2013-06-26 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de glucokinase et procédés pour les utiliser
|
ES2733348T3
(es)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
|
JP2011503081A
(ja)
|
2007-11-01 |
2011-01-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、AP−1および/またはNF−κB活性の調節剤として有用な非ステロイド性化合物、並びにその使用
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(fr)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
WO2009158380A1
(fr)
|
2008-06-24 |
2009-12-30 |
Bristol-Myers Squibb Company |
Modulateurs de cyclopentathiopène du récepteur glucocorticoïde, ap-1, et/ou activité nf-kappa b et utilisation de ceux-ci
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
US20110190322A1
(en)
*
|
2008-08-14 |
2011-08-04 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
KR101054911B1
(ko)
|
2008-10-17 |
2011-08-05 |
동아제약주식회사 |
디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
|
BRPI0923121A2
(pt)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Formas salinas de compostos orgânico
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
ES2548913T3
(es)
|
2009-09-11 |
2015-10-21 |
Probiodrug Ag |
Derivados heterocíclicos como inhibidores de glutaminil ciclasa
|
US20120294936A1
(en)
|
2009-11-13 |
2012-11-22 |
Astrazeneca Uk Limited |
Reduced mass metformin formulations
|
ES2689107T3
(es)
|
2009-11-13 |
2018-11-08 |
Astrazeneca Ab |
Formulaciones de tabletas bicapa
|
JP5784623B2
(ja)
|
2009-11-13 |
2015-09-24 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
速放性錠剤製剤
|
CN102753161A
(zh)
|
2009-11-27 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
|
JP2013523819A
(ja)
|
2010-04-06 |
2013-06-17 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
|
WO2011130459A1
(fr)
|
2010-04-14 |
2011-10-20 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
|
US8581001B2
(en)
|
2010-04-16 |
2013-11-12 |
Codman & Shurtleff |
Metformin-cysteine prodrug
|
WO2011131748A2
(fr)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Nouveaux inhibiteurs
|
WO2011138421A1
(fr)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combinaison thérapeutique
|
EP3124041A1
(fr)
|
2010-06-24 |
2017-02-01 |
Boehringer Ingelheim International GmbH |
Traitement du diabète
|
AU2011295837B2
(en)
|
2010-09-03 |
2015-06-18 |
Astrazeneca Uk Limited |
Drug formulations using water soluble antioxidants
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101871011B1
(ko)
|
2010-09-22 |
2018-06-25 |
아레나 파마슈티칼스, 인크. |
Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2012106303A1
(fr)
|
2011-02-01 |
2012-08-09 |
Bristol-Myers Squibb Company |
Formulations pharmaceutiques comprenant un composé amine
|
ES2664873T3
(es)
|
2011-03-01 |
2018-04-23 |
Synergy Pharmaceuticals Inc. |
Proceso de preparación de agonistas de guanilato ciclasa C
|
WO2012123563A1
(fr)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
|
WO2012135570A1
(fr)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
|
WO2012145361A1
(fr)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012145604A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
EP2532506A1
(fr)
|
2011-06-06 |
2012-12-12 |
Battenfeld-Cincinnati Germany GmbH |
Dispositif de tirage pour une extrudeuse
|
WO2012170702A1
(fr)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
|
ES2713566T3
(es)
|
2011-07-15 |
2019-05-22 |
Boehringer Ingelheim Int |
Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
|
WO2013055910A1
(fr)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(fr)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
WO2014074668A1
(fr)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
|
DK2925735T3
(da)
|
2012-11-20 |
2019-06-17 |
Lexicon Pharmaceuticals Inc |
Inhibitorer for natriumglucose-cotransporter 1
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
WO2015027021A1
(fr)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Dérivés imide et acylurée utilisés comme modulateurs du récepteur de glucocorticoïdes
|
EA201690938A1
(ru)
|
2013-11-05 |
2016-11-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
CA2979033A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
JP2018123065A
(ja)
*
|
2017-01-30 |
2018-08-09 |
株式会社明治 |
インスリン分泌促進用組成物
|
WO2018162722A1
(fr)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
|
US11253508B2
(en)
|
2017-04-03 |
2022-02-22 |
Coherus Biosciences, Inc. |
PPARy agonist for treatment of progressive supranuclear palsy
|
EP3461819B1
(fr)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibiteurs de la glutaminyl-cyclase
|
CA3105626A1
(fr)
|
2018-07-19 |
2020-01-23 |
Astrazeneca Ab |
Methodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
EP3856714A1
(fr)
|
2018-09-26 |
2021-08-04 |
Lexicon Pharmaceuticals, Inc. |
Formes cristallines de n-(1 -((2-(diméthylamino)éthyl)amino)-2-m éthyl-1 -oopropan-2-yl)-4-(4-(2-méthyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(méthylthio)tétrahydro-2h-pyran-2-yl)benzyl) phényl)butanamide et procédés de synthèse associés
|
WO2022022865A1
(fr)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Procédés de traitement d'une maladie rénale chronique avec de la dapagliflozine
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|